(2R,3S)-2-(3,4,5-Trihydroxyphenyl)chromane-3,5,7-triol

Catalog No. :
ACEJPK563
CAS No. :
970-73-0
Molecular Formula :
C15H14O7
Molecular Weight :
306.27

IUPAC Name:(2R,3S)-2-(3,4,5-trihydroxyphenyl)chromane-3,5,7-triol

(2R,3S)-2-(3,4,5-Trihydroxyphenyl)chromane-3,5,7-triol structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25mg98%$149.00Login to see priceIn stockInquiry
50mg98%$297.00Login to see priceIn stockInquiry
100mg98%$549.00Login to see priceIn stockInquiry
250mg98%$1111.00Login to see priceIn stockInquiry
1g98%$3437.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(2R,3S)-2-(3,4,5-Trihydroxyphenyl)chromane-3,5,7-triol
IUPAC Name(2R,3S)-2-(3,4,5-trihydroxyphenyl)chromane-3,5,7-triol
MDL No.MFCD06798946
Molecular FormulaC15H14O7
Molecular Weight306.27
SMILESO[C@@H]1[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1
InChI KeyXMOCLSLCDHWDHP-SWLSCSKDSA-N
SynonymACon1_000994 | Gallocatechol, (+-)- | 4-{1-Butyl-9-[1-(4,6-dimethyl-pyrimidine-5-carbonyl)-4-methyl-piperidin-4-yl]-2-oxo-3,0-diaza-spiro[5.5]undec-3-ylmethyl}-piperidine-1-carboxylic acid methyl ester | Gallocatechol | 2H-1-Benzopyran-3,5,7-triol, 3,4-di
CAS No.970-73-0
PubChem CID65084

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACEJPK563 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBGWJ891 route compound structure diagram
    ACBGWJ89127200-12-0 In Stock
  2. Then
  3. ACEJPK563 route product structure diagram
    ACEJPK563970-73-0 In Stock
Inquiry

2. ACEJPK563 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACEJPK563 route product structure diagram
    ACEJPK563970-73-0 In Stock
Inquiry

Comments (0)